These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2401 related articles for article (PubMed ID: 29375204)

  • 1. Metabolic and hepatic effects of liraglutide, obeticholic acid and elafibranor in diet-induced obese mouse models of biopsy-confirmed nonalcoholic steatohepatitis.
    Tølbøl KS; Kristiansen MN; Hansen HH; Veidal SS; Rigbolt KT; Gillum MP; Jelsing J; Vrang N; Feigh M
    World J Gastroenterol; 2018 Jan; 24(2):179-194. PubMed ID: 29375204
    [TBL] [Abstract][Full Text] [Related]  

  • 2. INT-767 improves histopathological features in a diet-induced
    Roth JD; Feigh M; Veidal SS; Fensholdt LK; Rigbolt KT; Hansen HH; Chen LC; Petitjean M; Friley W; Vrang N; Jelsing J; Young M
    World J Gastroenterol; 2018 Jan; 24(2):195-210. PubMed ID: 29375205
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Validity of biopsy-based drug effects in a diet-induced obese mouse model of biopsy-confirmed NASH.
    Baandrup Kristiansen MN; Veidal SS; Christoffersen C; Feigh M; Vrang N; Roth JD; Erickson M; Adorini L; Jelsing J
    BMC Gastroenterol; 2019 Dec; 19(1):228. PubMed ID: 31883514
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined obeticholic acid and elafibranor treatment promotes additive liver histological improvements in a diet-induced ob/ob mouse model of biopsy-confirmed NASH.
    Roth JD; Veidal SS; Fensholdt LKD; Rigbolt KTG; Papazyan R; Nielsen JC; Feigh M; Vrang N; Young M; Jelsing J; Adorini L; Hansen HH
    Sci Rep; 2019 Jun; 9(1):9046. PubMed ID: 31227742
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Superior reductions in hepatic steatosis and fibrosis with co-administration of a glucagon-like peptide-1 receptor agonist and obeticholic acid in mice.
    Jouihan H; Will S; Guionaud S; Boland ML; Oldham S; Ravn P; Celeste A; Trevaskis JL
    Mol Metab; 2017 Nov; 6(11):1360-1370. PubMed ID: 29107284
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Obese diet-induced mouse models of nonalcoholic steatohepatitis-tracking disease by liver biopsy.
    Kristiansen MN; Veidal SS; Rigbolt KT; Tølbøl KS; Roth JD; Jelsing J; Vrang N; Feigh M
    World J Hepatol; 2016 Jun; 8(16):673-84. PubMed ID: 27326314
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of ALT-801, a GLP-1 and glucagon receptor dual agonist, in a translational mouse model of non-alcoholic steatohepatitis.
    Nestor JJ; Parkes D; Feigh M; Suschak JJ; Harris MS
    Sci Rep; 2022 Apr; 12(1):6666. PubMed ID: 35461369
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatoprotective effects of the long-acting fibroblast growth factor 21 analog PF-05231023 in the GAN diet-induced obese and biopsy-confirmed mouse model of nonalcoholic steatohepatitis.
    Nielsen MH; Gillum MP; Vrang N; Jelsing J; Hansen HH; Feigh M; Oró D
    Am J Physiol Gastrointest Liver Physiol; 2023 May; 324(5):G378-G388. PubMed ID: 36852934
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased hepatoprotective effects of the novel farnesoid X receptor agonist INT-787 versus obeticholic acid in a mouse model of nonalcoholic steatohepatitis.
    Adorini L; Rigbolt K; Feigh M; Roth J; Erickson M
    PLoS One; 2024; 19(4):e0300809. PubMed ID: 38662778
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Liraglutide improves hepatic steatosis and metabolic dysfunctions in a 3-week dietary mouse model of nonalcoholic steatohepatitis.
    Duparc T; Briand F; Trenteseaux C; Merian J; Combes G; Najib S; Sulpice T; Martinez LO
    Am J Physiol Gastrointest Liver Physiol; 2019 Oct; 317(4):G508-G517. PubMed ID: 31460789
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening.
    Ratziu V; Harrison SA; Francque S; Bedossa P; Lehert P; Serfaty L; Romero-Gomez M; Boursier J; Abdelmalek M; Caldwell S; Drenth J; Anstee QM; Hum D; Hanf R; Roudot A; Megnien S; Staels B; Sanyal A;
    Gastroenterology; 2016 May; 150(5):1147-1159.e5. PubMed ID: 26874076
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Investigating fibrosis and inflammation in an ex vivo NASH murine model.
    Gore E; Bigaeva E; Oldenburger A; Jansen YJM; Schuppan D; Boersema M; Rippmann JF; Broermann A; Olinga P
    Am J Physiol Gastrointest Liver Physiol; 2020 Feb; 318(2):G336-G351. PubMed ID: 31905025
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Elafibranor improves diet-induced nonalcoholic steatohepatitis associated with heart failure with preserved ejection fraction in Golden Syrian hamsters.
    Briand F; Maupoint J; Brousseau E; Breyner N; Bouchet M; Costard C; Leste-Lasserre T; Petitjean M; Chen L; Chabrat A; Richard V; Burcelin R; Dubroca C; Sulpice T
    Metabolism; 2021 Apr; 117():154707. PubMed ID: 33444606
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Towards a standard diet-induced and biopsy-confirmed mouse model of non-alcoholic steatohepatitis: Impact of dietary fat source.
    Boland ML; Oró D; Tølbøl KS; Thrane ST; Nielsen JC; Cohen TS; Tabor DE; Fernandes F; Tovchigrechko A; Veidal SS; Warrener P; Sellman BR; Jelsing J; Feigh M; Vrang N; Trevaskis JL; Hansen HH
    World J Gastroenterol; 2019 Sep; 25(33):4904-4920. PubMed ID: 31543682
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Obeticholic acid raises LDL-cholesterol and reduces HDL-cholesterol in the Diet-Induced NASH (DIN) hamster model.
    Briand F; Brousseau E; Quinsat M; Burcelin R; Sulpice T
    Eur J Pharmacol; 2018 Jan; 818():449-456. PubMed ID: 29155143
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Elafibranor and liraglutide improve differentially liver health and metabolism in a mouse model of non-alcoholic steatohepatitis.
    Perakakis N; Stefanakis K; Feigh M; Veidal SS; Mantzoros CS
    Liver Int; 2021 Aug; 41(8):1853-1866. PubMed ID: 33788377
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biochemical and histological characterisation of an experimental rodent model of non-alcoholic steatohepatitis - Effects of a peroxisome proliferator-activated receptor gamma (PPAR-γ) agonist and a glucagon-like peptide-1 analogue.
    Daniels SJ; Leeming DJ; Detlefsen S; Bruun MF; Hjuler ST; Henriksen K; Hein P; Karsdal MA; Brockbank S; Cruwys S
    Biomed Pharmacother; 2019 Mar; 111():926-933. PubMed ID: 30841472
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatoprotective effects of semaglutide, lanifibranor and dietary intervention in the GAN diet-induced obese and biopsy-confirmed mouse model of NASH.
    Møllerhøj MB; Veidal SS; Thrane KT; Oró D; Overgaard A; Salinas CG; Madsen MR; Pfisterer L; Vyberg M; Simon E; Broermann A; Vrang N; Jelsing J; Feigh M; Hansen HH
    Clin Transl Sci; 2022 May; 15(5):1167-1186. PubMed ID: 35143711
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Obeticholic acid protects against hepatocyte death and liver fibrosis in a murine model of nonalcoholic steatohepatitis.
    Goto T; Itoh M; Suganami T; Kanai S; Shirakawa I; Sakai T; Asakawa M; Yoneyama T; Kai T; Ogawa Y
    Sci Rep; 2018 May; 8(1):8157. PubMed ID: 29802399
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nonalcoholic steatohepatitis severity is defined by a failure in compensatory antioxidant capacity in the setting of mitochondrial dysfunction.
    Boland ML; Oldham S; Boland BB; Will S; Lapointe JM; Guionaud S; Rhodes CJ; Trevaskis JL
    World J Gastroenterol; 2018 Apr; 24(16):1748-1765. PubMed ID: 29713129
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 121.